Critical Insights From Pacific Biosciences Analyst Ratings: What You Need To Know
Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Pacific Biosciences (NASDAQ:PACB) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 2 | 6 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 3 | 0 | 0 |
| 2M Ago | 2 | 2 | 3 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Pacific Biosciences, revealing an average target of $3.64, a high estimate of $8.00, and a low estimate of $2.00. A decline of 57.92% from the prior average price target is evident in the current average.
Diving into Analyst Ratings: An In-Depth Exploration
The analysis of recent analyst actions sheds light on the perception of Pacific Biosciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tycho Peterson | Jefferies | Announces | Buy | $4.00 | - |
| Tejas Savant | Morgan Stanley | Lowers | Equal-Weight | $4.00 | $10.00 |
| David Westenberg | Piper Sandler | Lowers | Neutral | $2.00 | $6.50 |
| Luke Sergott | Barclays | Lowers | Equal-Weight | $2.00 | $3.00 |
| Matthew Sykes | Goldman Sachs | Lowers | Neutral | $2.50 | $7.00 |
| Eve Burstein | Bernstein | Lowers | Outperform | $2.50 | $9.00 |
| Matthew Sykes | Goldman Sachs | Lowers | Neutral | $2.50 | $7.00 |
| Sung Ji Nam | Scotiabank | Lowers | Sector Outperform | $8.00 | $15.00 |
| Daniel Brennan | TD Cowen | Lowers | Buy | $2.50 | $12.00 |
| Luke Sergott | Barclays | Lowers | Equal-Weight | $3.00 | $8.00 |
| Matthew Sykes | Goldman Sachs | Lowers | Buy | $7.00 | $9.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Pacific Biosciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Pacific Biosciences compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Pacific Biosciences's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Pacific Biosciences's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Pacific Biosciences analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Pacific Biosciences's Background
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Financial Milestones: Pacific Biosciences's Journey
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Pacific Biosciences faced challenges, resulting in a decline of approximately -0.23% in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pacific Biosciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -201.44%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Pacific Biosciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -11.58%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Pacific Biosciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -4.58% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Pacific Biosciences's debt-to-equity ratio surpasses industry norms, standing at 1.44. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
The Basics of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.